SweetBiotix® Update
OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")
SweetBiotix® Update
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes provides an update on its SweetBiotix® product range for new and existing investors.
On 24 November 2025, the Company announced it had achieved a major technical and commercial breakthrough with the introduction of a new enzyme that delivers higher yields and a purer and cleaner tasting product. This enzyme has a one-step enzymic process which simplifies manufacture and reduces ingredient and production costs.
The Company held a SweetBiotix shareholder presentation and tasting session on 24 June 2026, where shareholders were able to sample SweetBiotix with three volunteers joining a 'tasting panel' comparing SweetBiotix to sugar. Investors reported a clean tasting product with no aftertaste and sweetness slightly higher than sugar. The Company also presented a pathway to production and commercialisation.
The Company reports it has made good progress on this pathway and has:-
1. Undertaken independent testing by The Flavour and Sensory Science Centre at the University of Reading using an expert sensory panel which showed that the Company has successfully developed a sweet fibre approximately 100X as sweet as sugar with a clean taste. This creates the potential for a range of finished products ranging from 1:1 sweetness of sugar up to 100X the sweetness according to application need without any flavour off notes as occur in existing products.
2. Carried out structural analysis using Nuclear Magnetic Resonance (NMR) to confirm prebiotic modification of Reb A and that we have created a unique ingredient. Structural analysis is important in IP filings to protect the invention.
3. Produced more SweetBiotix samples at laboratory scale to share with beverage, confectionary, and food companies who have expressed interest with the first samples being sent out at the start of September. These include well known food, beverage and confectionary brands as well as a recent interest from a major global beverage Company who we have sent SweetBiotix samples.
4. Received and negotiated manufacturing agreements with three manufacturers. Subject to finalising an agreement and the manufacturer's production timetable, the Company is targeting receipt of initial product samples around the end of 2026.
Work continues in line with the pathway to production and commercialisation with further progress updates to be provided in due course.
Stephen O'Hara, CEO of OptiBiotix Health plc said: "The discovery of the new enzyme has reduced the complexity of manufacturing and increased the number of potential partners able to produce SweetBiotix. Whilst there remains a number of challenges, we now have a clear pathway to production and commercialisation and believe this discovery has led to a material improvement in the likelihood of successful manufacture and the commercial potential of our SweetBiotix products. We are encouraged by the level of interest in SweetBiotix from major partners, including a recent approach from a global beverage company."
View the full announcement and submit questions to management via our website: https://optibiotix.com/link/r6wpdP
|
For further information, please contact: OptiBiotix Health plc |
||
|
Neil Davidson, Chairman |
|
|
|
Stephen O'Hara, Chief Executive
|
|
|
|
Cairn Financial Advisers LLP (NOMAD and Broker) |
Tel: 020 7213 0880 |
|
|
Liam Murray / Ludovico Lazzaretti / James Western
|
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE